回盛生物
(300871)
| 流通市值：19.25亿 | | | 总市值：19.25亿 |
| 流通股本：1.66亿 | | | 总股本：1.66亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 237,278,933.04 | 350,799,820.21 | 286,067,710.87 | 293,609,731.56 |
| 应收票据及应收账款 | 383,312,881.09 | 334,106,185.37 | 333,505,174.4 | 328,626,808.26 |
| 其中：应收票据 | 32,855,877.05 | 17,328,911.85 | 12,776,207.1 | 10,112,183.6 |
| 应收账款 | 350,457,004.04 | 316,777,273.52 | 320,728,967.3 | 318,514,624.66 |
| 应收款项融资 | 34,266,616.14 | 19,474,555.59 | 41,755,066.42 | 40,484,046.22 |
| 预付款项 | 58,465,173.64 | 22,178,782.34 | 35,819,939.21 | 62,279,961.6 |
| 其他应收款合计 | 3,770,892.04 | 3,456,205.39 | 3,153,829.72 | 2,775,736.63 |
| 存货 | 251,244,479.5 | 288,951,021.72 | 278,952,041.56 | 228,670,224.54 |
| 其他流动资产 | 8,664,203.32 | 10,795,947.57 | 12,185,975.25 | 5,277,308.58 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,209,306,834.79 | 1,235,017,572.57 | 1,277,604,103.83 | 1,265,980,935.65 |
| 非流动资产: | | | | |
| 投资性房地产 | 10,641,233.25 | 10,815,637.67 | 10,990,042.09 | 11,164,446.51 |
| 固定资产 | 1,522,390,094.03 | 1,490,728,306.5 | 1,491,391,198.85 | 1,513,030,521.14 |
| 在建工程 | 25,442,016.66 | 56,066,094.92 | 70,504,989.82 | 53,128,395.44 |
| 无形资产 | 113,725,190.21 | 114,161,871.78 | 115,138,644.88 | 104,171,673.33 |
| 长期待摊费用 | 2,064,999.71 | 2,231,288.72 | 2,504,323.82 | 2,717,765.25 |
| 递延所得税资产 | 25,544,475.65 | 24,670,320.47 | 22,591,295.92 | 21,653,385.75 |
| 其他非流动资产 | 3,418,474.64 | 7,379,466.53 | 3,113,829.55 | 3,613,339.05 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,703,226,484.15 | 1,706,052,986.59 | 1,716,234,324.93 | 1,709,479,526.47 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,912,533,318.94 | 2,941,070,559.16 | 2,993,838,428.76 | 2,975,460,462.12 |
| 流动负债: | | | | |
| 短期借款 | 370,179,161 | 339,021,054 | 320,348,032 | 240,318,254.06 |
| 应付票据及应付账款 | 432,575,726.49 | 369,125,433.62 | 418,318,514.58 | 472,468,943.52 |
| 其中：应付票据 | 207,962,025.84 | 146,954,674.91 | 169,469,534.6 | 154,575,517.66 |
| 应付账款 | 224,613,700.65 | 222,170,758.71 | 248,848,979.98 | 317,893,425.86 |
| 合同负债 | 16,723,287.58 | 14,254,484.35 | 14,422,903.03 | 10,265,735.99 |
| 应付职工薪酬 | 18,062,279.26 | 14,288,194.95 | 14,528,724.56 | 21,982,292.43 |
| 应交税费 | 4,200,346.19 | 3,033,310.17 | 2,141,234.77 | 8,134,681.06 |
| 其他应付款合计 | 25,260,230.97 | 18,484,682.3 | 21,234,276.68 | 23,791,044.7 |
| 一年内到期的非流动负债 | 14,352,321.49 | 13,758,348.33 | 2,013,400.89 | 268,453.84 |
| 其他流动负债 | 11,772,719.49 | 9,568,431.68 | 4,268,977.69 | 3,847,079.18 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 893,126,072.47 | 781,533,939.4 | 797,276,064.2 | 781,076,484.78 |
| 非流动负债: | | | | |
| 长期借款 | 35,000,000 | 40,000,000 | - | - |
| 应付债券 | 492,025,133.3 | 616,743,192.86 | 609,142,164.37 | 601,656,976.01 |
| 递延收益 | 60,148,965.14 | 61,958,484.12 | 60,715,289.78 | 62,338,822.34 |
| 递延所得税负债 | 7,973,682.59 | 9,953,619.78 | 16,077,723.39 | 20,262,116.87 |
| 其他非流动负债 | 845,000 | 845,000 | 845,000 | 845,000 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 595,992,781.03 | 729,500,296.76 | 686,780,177.54 | 685,102,915.22 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,489,118,853.5 | 1,511,034,236.16 | 1,484,056,241.74 | 1,466,179,400 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 165,765,503 | 165,764,170 | 165,887,230 | 165,887,194 |
| 其他权益工具 | 102,470,647.95 | 126,903,438.43 | 126,903,438.43 | 126,903,619.73 |
| 资本公积 | 869,930,047.93 | 855,959,679.99 | 857,206,500.67 | 874,007,691.88 |
| 减:库存股 | 17,404,202.28 | 15,775,070.28 | 18,174,740.28 | 52,421,063.28 |
| 其他综合收益 | -785,663.87 | -1,605,959.83 | -556,600.78 | -18,355.99 |
| 盈余公积 | 52,979,506 | 52,979,506 | 52,979,506 | 52,979,506 |
| 未分配利润 | 249,731,309.85 | 245,510,934.65 | 325,536,852.98 | 341,942,469.78 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,422,687,148.58 | 1,429,736,698.96 | 1,509,782,187.02 | 1,509,281,062.12 |
| 少数股东权益 | 727,316.86 | 299,624.04 | - | 0 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,423,414,465.44 | 1,430,036,323 | 1,509,782,187.02 | 1,509,281,062.12 |
| 负债和股东权益合计 | 2,912,533,318.94 | 2,941,070,559.16 | 2,993,838,428.76 | 2,975,460,462.12 |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |